explore -WSS

explore

author：fashion 2025-08-12 09:09:47 - browse：2337

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Faced with fears of OxyContin misuse, sales reps touted its safety

knowledge

focus

Wikipedia

WSS

Pharma budget tightening trickles down to Doximity

More regulation could be coming for drug ads

More regulation could be coming for drug ads

Newly revealed memo details efforts to keep Trump in power following election loss

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Kim Kardashian sparks debate on benefits of full

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Duchenne breakthrough therapy leaves behind pioneering families

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

State Dept. review finds Biden bears some blame for Afghanistan failures

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Trump demands the U.S. pay no more for drugs than other countries … again

CDC launches VaccineFinder tool to locate Covid

ChatGPT in medicine: STAT answers readers' burning questions

TB outbreak tied to bone grafts underscores testing shortcomings

Hollywood unions extend contract negotiations for actors

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

focus

Target recalls 2.2 million additional candles due to laceration, burn hazards

Discs beat pads, tampons for heavy menstrual flow, new study shows

Choosing scientific sides in the fight against Alzheimer's

The history of OxyContin, told through Purdue Pharma documents

Newly revealed memo details efforts to keep Trump in power following election loss

Sage's campaign to raise awareness of postpartum depression hits a nerve

knowledge

focus

Wikipedia

hotspot